These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30603325)

  • 1. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Ogawa A; Ishikura K; Kanehara H; Hisada A; Notumata K; Okafuji K; Toya D
    Diabetol Int; 2017 Jun; 8(2):218-227. PubMed ID: 30603325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Tohyama H; Aoki K; Kanehara H; Hisada A; Okafuji K; Toya D
    J Clin Transl Endocrinol; 2016 Dec; 6():1-7. PubMed ID: 29067237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Characteristics Of Abdominal Fat Distribution In Japanese Adolescents With Type 2 Diabetes Mellitus.
    Abe Y; Urakami T; Hara M; Yoshida K; Mine Y; Aoki M; Suzuki J; Saito E; Yoshino Y; Iwata F; Okada T; Morioka I
    Diabetes Metab Syndr Obes; 2019; 12():2281-2288. PubMed ID: 31807041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial.
    Han E; Lee YH; Lee BW; Kang ES; Cha BS
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31963648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.
    Koshizaka M; Ishikawa K; Ishibashi R; Takahashi S; Sakamoto K; Yokoh H; Baba Y; Ide S; Ide K; Ishikawa T; Onishi S; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Maezawa Y; Yokote K
    Diabetes Ther; 2021 Jan; 12(1):183-196. PubMed ID: 33098565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.
    Fukuda T; Bouchi R; Terashima M; Sasahara Y; Asakawa M; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Ther; 2017 Aug; 8(4):851-861. PubMed ID: 28616806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Feb; 8(2):116-25. PubMed ID: 26767080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
    Ito D; Shimizu S; Haisa A; Yanagisawa S; Inoue K; Saito D; Sumita T; Yanagisawa M; Uchida Y; Inukai K; Shimada A
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38775319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
    Ishihara H; Yamaguchi S; Nakao I; Sakatani T
    Diabetes Ther; 2018 Aug; 9(4):1549-1567. PubMed ID: 29926400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin.
    Kato M; Sakai K; Saito K; Tsutsui K; Yamashita S; Kato N
    Diabetol Int; 2017 Aug; 8(3):275-285. PubMed ID: 30603333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin.
    Yamauchi Y; Nakamura A; Takahashi K; Takase T; Yamamoto C; Yokota I; Atsumi T; Miyoshi H
    Endocr J; 2019 Nov; 66(11):995-1000. PubMed ID: 31292303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
    Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
    Kawata T; Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Jul; 9(7):586-595. PubMed ID: 28611859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
    Yoneda M; Iwasaki T; Fujita K; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Wada K; Saito S; Terauchi Y; Nakajima A
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S15-21. PubMed ID: 17331160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.